Drugs / IMC-CS4
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial · 1 met primary | ||||||
| Phase 0 | NCT03153410 | Sep 2018 → Mar 2022 | malignant pancreatic neoplasm | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | Met primary |
| Phase 11 trial | ||||||
| Phase 1 | NCT01346358 | Jun 2011 → May 2018 | neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMC-CS4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03153410 ↗ |
| Action | Inhibit | “CSF1 receptor blockade (IMC-CS4)” PMID 41878443 ↗ Mar 2026 |
| Route | Intravenous | “intravenous (IV) infusion” NCT03153410 ↗ |
| Target | CSF1R | “anti-CSF1R agent IMC-CS4” PMID 41878443 ↗ Mar 2026 |